Papanicolaou Screening in Developing Countries: An Idea Whose Time Has Come

American Journal of Clinical Pathology

Volumn 121, Issue 3, 2004, Pages 315-320

  Suba, Eric J ^a   Raab, Stephen S ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Developing countries; Direct visual inspection (DVI); HPV screening; HPV vaccines; Papanicolaou screening; Quality assurance improvement; Visual cervical screening; Visual inspection with acetic acid (VIA)

Indexed keywords

ACETIC ACID; CANCER VACCINE;

CANCER RESEARCH; CANCER SCREENING; COST; DEVELOPING COUNTRY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; PAPANICOLAOU TEST; POLITICS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SOCIAL ASPECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VISUAL CERVICAL SCREENING; WART VIRUS;

EID: 1542347931     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/G40XQBWNPV7MK9TY     Document Type: Review

References (67)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Vol VII. Lyon, France: International Agency for Research on Cancer; 1997. IARC Scientific Publication 143.
2. Stewart BW, Kleihues P, eds. Global Cancer Report. Geneva, Switzerland: World Health Organization; 2003.
3. Screening for Cervical Cancer: File Inventory, Systematic Evidence Review Number 25. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at: http://www.ahrq.gov/clinic/prev/crvcainv.htm. Accessed December 14, 2003.
4. Miller AB. Quality assurance in screening strategies. Review. Virus Res. 2002;89:295-299.
5. Cornelison TL, Montz FJ, Bristow RE, et al. Decreased incidence of cervical cancer in Medicare-eligible California women. Obstet Gynecol. 2002;100:79-86.
6. Hartmann KE, Nanda K, Hall S, et al. Technologic advances for evaluation of cervical cytology: is newer better? Obstet Gynecol Surv. 2001;56:765-774.
7. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol. 1999;94:307-310.
8. Suba EJ, Raab SS, on behalf of the Viet/American Cervical Cancer Prevention Project. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam [letter]. Cancer. 2002;94:2314-2316.
9. Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.
10. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
11. Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta. 1998;1423:M1-M8.
12. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 2003;95:1128-1137.
13. Sherman ME, Schiffman MH, Strickler H, et al. Prospects for a prophylactic HPV vaccine: rationale and future implications for cervical cancer screening. Diagn Cytopathol. 1998;18:5-9.
14. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789.
15. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine. 1999;17:646-652.
16. Sankaranarayanan R. Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 17 January 2002. Cervical cancer in developing countries. Trans R Soc Trop Med Hyg. 2002;96:580-585.
17. Cuzick J. Screening for cancer: future potential. Eur J Cancer. 1999;35:685-692.
18. Hakama M. Screening for cervical cancer: experience of the Nordic countries. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, England: Blackwell Sciences; 1997:190-199.
19. The Appalachia Leadership Initiative on Cancer. Sowing Seeds in the Mountains: Community-Based Coalitions for Cancer Prevention and Control. Bethesda, MD: National Cancer Institute; 1994:1. NIH publication 94-3779.
20. Suba EJ, Hung NC, Duc NB, on behalf of the Viet/American Cervical Cancer Prevention Project. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. Cancer. 2001;91:928-939.
21. Jamison DT, Mosley H, Bobadilla J, et al, eds. Disease Control Priorities in Developing Countries. New York, NY: Oxford University Press; 1993.
22. Chirenje ZM, Rusakaniko S, Kirumbi L, et al. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ. 2001;79:127-132.
23. Nascimento CM, Eluf-Neto J, Rego RA. Pap test coverage in Sao Paulo municipality and characteristics of the women tested [published correction appears in Bull Pan Am Health Organ. 1997;2:106]. Bull Pan Am Health Organ. 1996;30:302-312.
24. Nascimento CM, Eluf-Neto J, Rego RA. Pap test coverage in Sao Paulo municipality and characteristics of the women tested [published correction appears in Bull Pan Am Health Organ. 1997;2:106]. Bull Pan Am Health Organ. 1996;30:302-312.
25. Gajalakshmi CK, Krishnamurthi S, Ananth R, et al. Cervical cancer screening in Tamilnadu, India: a feasibility study of training the village health nurse. Cancer Causes Control. 1996;7:520-524.
26. Suba EJ, Raab SS. Population-based Pap screening in Cameroon [letter]. Acta Cytol. 2003;47:948-949.
27. The World Bank. Gross national income per capita in 2001, country-specific. Available at: http://www.worldbank.org/data/databytopic/GNIPC.pdf. Accessed April 5, 2003.
28. United States Department of Health and Human Services. United States Congress. Social Security Act, Section 1833(h). Washington, DC, 1995.
29. Raab SS. The cost-effectiveness of cervical vaginal rescreening. Am J Clin Pathol. 1997;108:525-536.
30. Studer-Ellis E, Gold JS, Jones RF. Trends in US medical school faculty salaries, 1988-1989 to 1998-1999. JAMA. 2000;284:1130-1135.
31. Balanced Budget Refinement Act §224, Pub L No. 106-113 (2000).
32. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107-3115.
33. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst. 2002;94:1469-1483.
34. Robyr R, Nazeer S, Vassilakos P, et al. Feasibility of cytology-based cervical cancer screening in rural Cameroon. Acta Cytol. 2002;46:1110-1116.
35. US Preventive Services Task Force. Screening for Cervical Cancer. Rockville, MD: Agency for Healthcare Research and Quality, Dept of Health and Human Services; January 2003. AHRQ publication APPIP03-0004. Available at: http://www.ahcpr.gov/clinic/3rduspstf/cervcan/cervcanwh.pdf. Accessed April 5, 2003.
36. Obwegeser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? a prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases. Acta Cytol. 2001;45:709-714.
37. Coste J, Cochand-Priollet B, de Cremoux P, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003;326:733-737.
38. Austin RM. The detection of precancerous cervical lesions can be significantly increased. Arch Path Lab Med. 2003;127:143-145.
39. Sellors J. Response to Pap screening in developing countries. Cervical-Cancer-L Archives. April 2002. Available at: http://info.path.org/cgi-bin/wa?A1=ind0204&L=cervical-cancer-1#7. Accessed April 5, 2003.
40. Richart RM, Sankaranarayanan R, Robles S, et al. Cervical cancer screening strategies for developing countries. Contemp Ob Gyn. January 2001:71-79, 100-127.
41. Jayant K, Rao RS, Nene BM, et al. Improved stage at diagnosis of cervical cancer with increased awareness in a rural Indian population. Int J Cancer. 1995;63:161-163.
42. Denny L, Kuhn L, Pollack A, et al. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer. 2000;89:826-833.
43. Belinson JL, Qiao Y, Pretorius R, et al. Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer. 1999;9:411-417.
44. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
45. Pan Q, Belinson JL, Li L, et al. A thin-layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study. Acta Cytol. 2003;47:45-50.
46. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
47. Kuhn L, Denny L, Pollack A, et al. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst. 2000;92:818-825.
48. Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000;283:81-86.
49. Womack SD, Chirenje ZM, Blumenthal PD, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG. 2000;107:33-38.
50. Blumenthal PD, Gaffikin L, Chirenje ZM, et al. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet. 2001;72:47-53.
51. Denny L, Kuhn L, Pollack A, et al. Direct visual inspection for cervical cancer screening. Cancer. 2002;94:1699-1707.
52. Sasieni P, Cuzick J, Boyle P, et al. Routine audit is an ethical requirement of screening [letter]. BMJ. 2001;322:1179.
53. United States Congress. Clinical Laboratory Improvement Amendments of 1988 (CLIA). September 1988: House Report 100-899.
54. Miller AB. Cervical Cancer Screening Programmes: Managerial Guidelines. Geneva, Switzerland: World Health Organization; 1992.
55. Belinson JL, Pretorius RG. Cervical cancer screening by simple visual inspection after acetic acid [letter]. Obstet Gynecol. 2002;99:518.
56. Goldie SJ, Kuhn L, Denny L, et al. Cervical cancer screening in developing countries [letter]. JAMA. 2001;286:3079-3081.
57. Program for Appropriate Technology in Health (PATH). Summary of Proceedings: Consultative Forum on Cervical Cancer Prevention in Low-Resource Settings [monograph online]. 2001. Available at: http://www.path.org/Files/CXCA-Conslt-Forum.pdf. Accessed April 5, 2003.
58. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001;79:954-962.
59. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-1757.
60. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. JAMA. 2001;286:1232-1234.
61. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-465.
62. Basu P, Sankaranarayanan R, Mandal R, et al. Evaluation of downstaging in the detection of cervical neoplasia in Kolkata, India. Int J Cancer. 2002;100:92-96.
63. Sankaranarayanan R, Syamalakumari B, Wesley R, et al. Visual inspection as a screening test for cervical cancer control in developing countries. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, England: Blackwell Sciences; 1997:411-421.
64. Denny L, Kuhn L, Risi L, et al. Two-stage cervical cancer screening: an alternative for resource-poor settings. Am J Obstet Gynecol. 2000;183:383-388.
65. Wright TC Jr, Menton M, Myrtle JF, et al. Visualization techniques (colposcopy, direct visual inspection, and spectroscopic and other visual methods): summary of task force 7. Acta Cytol. 2002;46:793-800.
66. Wright TC Jr, Denny L, Kuhn L, et al. Use of visual screening methods for cervical cancer screening. Obstet Gynecol Clin North Am. 2002;29:701-734.
67. DeAngelis CD. Conflict of interest and the public trust [editorial]. JAMA. 2000;284:2237-2238.